SEC gives go-ahead to St. Jude's takeover of Thoratec; FDA approves trials of minimally invasive heart procedure;

@FierceMedDev: ICYMI Friday: Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Updated $ABT's interest in $STJ w/ info from old article on their prior partnership. Neat to add context from 2012. Article | Follow @VarunSaxena2

@EmilyWFierce: $GOOG and $SNY are teaming up for #diabetes monitoring. More from the WSJ | Follow @EmilyWFierce

> The SEC has cleared St. Jude Medical's ($STJ) acquisition of LVAD maker Thoratec ($THOR) for $3.4B. The deal is expected to close in Q4, and must still receive the approval of Thoratec's shareholders. More

> Mitralign received an investigational device exemption (IDE) from the FDA to begin early feasibility studies of its Percutaneous Tricuspid Valve Annuloplasty System. "Percutaneous repair of the tricuspid valve represents one of the largest remaining unmet needs in the structural heart space," said Mitralaign CEO Rick Geoffrion. "We mimic a known surgical procedure but do not require open heart surgery, providing a potential treatment option for a large number of patients that are too sick for surgical intervention. More

Biotech News

@FierceBiotech: Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential. Article | Follow @FierceBiotech

@JohnCFierce: Amicus bags PhIII rare disease drug in $847M Scioderm buyout. News | Follow @JohnCFierce

@DamianFierce: Missed the FDA biosimilar-naming thing because vacation, but I'm a big fan of the phrase "suffix devoid of meaning." More | Follow @DamianFierce

> Intercept wins priority review for OCA. Item

> Sanofi buys into Google's biotech future, pairing up in diabetes. Story

> Bayer takes its heart-failure drug into Phase III after a mid-stage success. Report

> Step 3: After an immunotherapy makeover, CytomX files $100M IPO. More

Pharma News

@FiercePharma: ICYMI: Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuse. Article | Follow @FiercePharma

@EricPFierce: Majority of Mylan shareholders approve buyout of Perrigo, despite adamant opposition by its management. Press release | Follow @EricPFierce

@CarlyHFierce: 'No signal' of heart failure risk with Merck's Januvia, analysis confirms. Article | Follow @CarlyHFierce

> Dutch pension fund pulls out of Mylan amid death penalty drug concerns. Story

> Can Baxalta hold off Shire with its own bid for Ariad? More

> Patient education 'useless' when it comes to Eliquis adherence: study. Report

Animal Health News

> Denver cannabis seller teams with vet to launch pet wellness line. Item

> Cornell U spotlights veterinary profession on Nat Geo reality TV show. News

> Patterson shares fall on missed sales and earnings targets. More

> Young entrepreneur shows off veterinary product at White House Demo Day. Story

> Academic docs and biotechs partner with veterinarians to find cancer cures. Article

Biotech IT News

> Ginkgo Bioworks allies with Ajinomoto to expand into amino acid production. Item

> Venter's HLI nabs Millennium Health COO to oversee global expansion. Report

> Mytrus makes electronic informed consent breakthrough in U.K. Story

> How openFDA's 'crazy collision' of Silicon Valley and federal culture is reshaping the regulator. More

> UCL taps Elsevier resource to advance drug repurposing research. Article

Pharma Marketing News

> The 'Kardashian Effect' on pharma begs the question: Does social media influence drug requests? Story

> The need-to-know from ESC (so far): Merck, BMS, Pfizer and Sanofi. More

> Repatha vs. Praluent matchup has Amgen, Sanofi zeroing in on key details. Article

> Dutch pension fund dumps Mylan on worries about death penalty drug. Item

> Want to improve drug adherence, pharma? Get tracking. More